FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549	
------------------------	--

Washington, D.C. 20040	OMB APPROVAL			
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287		
	Estimated average bure	den		

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							(,			,									
1. Name and Address of Reporting Person* <u>Swisher Daniel N JR</u>						2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]									Relationship of Reporting Person(state all applicable) X Director				suer vner	
	•	irst) ERAPEUTICS	(Middle))		3. Date of Earliest Transaction (Month/Day/Year) 04/05/2021									Officer below)	(give title		Other (s below)	specify	
149 COMMONWEALTH DRIVE						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) MENLO	eet) ENLO PARK CA 94025														X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																	
		Tab	le I - N	Non-Deri	vative	e Sec	uriti	ies Ad	cquire	d, D	isposed o	of, or B	enefici	ally	Owned	i				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye					Execution Date,			3. Transa Code (I 8)		4. Securities Disposed Of	Acquired (D) (Instr	(A) or 3, 4 and	5. Amount o Securities Beneficially Owned Follo Reported		es ially Following	Form (D) o		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price		Transac	action(s) 3 and 4)			(111501.4)	
Common Stock 04/05/202					021	21			M ⁽¹⁾		7,500	A	\$6.5	\$6.55		7,500		D		
Common Stock 04/05/202				021	21			S ⁽¹⁾		7,500	D	\$24.13	24.1382(2)		0		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	r) if any	emed tion Date, n/Day/Year)	4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owne Form: Direct or Ind (I) (Ins	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ect (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amour or Number of Shares	er						
Stock Option (Right to Buy)	\$6.55	04/05/2021			M ⁽¹⁾			7,500	(3)	06/18/2025	Common Stock	7,500)	\$0.00	42,500)	D		

Explanation of Responses:

- 1. The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction.
- 2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from \$23.95 to \$24.54 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from Issuer upon request.
- 3. Fully exercisable.

Remarks:

/s/ Joseph Douglas Lyon, Attorney-in-Fact for Daniel N. 04/07/2021 Swisher, Jr.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.